Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results

Darell D. Bigner, Mark T. Brown, Allan H. Friedman, R. Edward Coleman, Gamal Akabani, Henry S. Friedman, Wade L. Thorstad, Roger E. McLendon, Sandra H. Bigner, Xiao Guang Zhao, Charles N. Pegram, Carol J. Wikstrand, James E. Herndon, Nicholas A. Vick, Nina Paleologos, Ilkcan Cokgor, James M. Provenzale, Michael R. Zalutsky

Research output: Contribution to journalArticlepeer-review

170 Scopus citations


Purpose: To determine the maximum-tolerated dose (MTD) of iodine 131 (131I)-labeled 81C6 monoclonal antibody (mAb) in brain tumor patients with surgically created resection cavities (SCRCs) and to identify any objective responses to this treatment. Methods: In this phase I trial, eligible patients were treated with a single injection of 131I-labeled 81C6. Cohorts of three to six patients were treated with escalating dosages of 131I (starting dose of 20 mCi with a 20-mCl escalation in subsequent cohorts) administered through an Ommaya reservoir in the SCRC. Patients were followed up for toxicity and response until death or for a minimum of 1 year after treatment. The SCRC patients, who were previously irradiated, were followed up without additional treatment unless progressive disease was identified. Results: We administered 36 treatments of 131I doses up to 120 mCi to 34 previously irradiated patients with recurrent or metastatic bran tumors. Dose-limiting toxicity was reached at 120 mCi and was limited to neuro-logic or hematologic toxicity. None of the patients treated with less than 120 mCi developed significantly neurologic toxicity; one patient developed major hematologic toxicity (MHT). The estimated median survival for patients with glioblastoma multiforme (GBM) and for all patients was 56 and 60 weeks, respectively. Conclusion: The MTD for administration of 131I- labeled 81C6 into the SCRCs of previously irradiated patients with recurrent primary or metastatic brain tumors was 100 mCi. The dose-limiting toxicity was neurologic toxicity. We are encouraged by the minimal toxicity and survival in this phase I trial. Radiolabeled mAbs may improve the current therapy for brain tumor patients.

Original languageEnglish
Pages (from-to)2202-2212
Number of pages11
JournalJournal of Clinical Oncology
Issue number6
StatePublished - Jun 1998


Dive into the research topics of 'Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results'. Together they form a unique fingerprint.

Cite this